Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $18.22 USD
Change Today 0.00 / 0.00%
Volume 0.0
RCDTF On Other Exchanges
RCDTF is not on other exchanges.
As of 8:10 PM 03/18/15 All times are local (Market data is delayed by at least 15 minutes).

recordati spa (RCDTF) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/18/15 - $18.28
52 Week Low
05/29/14 - $16.70
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for RECORDATI SPA (RCDTF)

Related News

No related news articles were found.

recordati spa (RCDTF) Related Businessweek News

No Related Businessweek News Found

recordati spa (RCDTF) Details

Recordati S.p.A. engages in the research, development, manufacture, marketing, and sale of pharmaceuticals. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, cosmetics, dermatology, dietary supplements, musculo-skeletal disorders and analgesia, pregnancy test, urology, OTC/non-prescription pharmaceuticals, allergy, antiinfectives, central nervous system, endocrinology, gastrointestinal, gynecology, obstetrics, nutrition and related areas, immunosuppressants, pediatrics, pneumology, hematology, oncology, respiratory, and generics. It primarily offers Zanidip (lercanidipine), a calcium channel blocker for the treatment of hypertension. The company’s product development pipeline includes Carbaglu, which is approved in the European Union and is under Phase III clinical trial in the United States for the treatment of organic acidemias; Zanipress that is approved in the European Union to treat essential hypertension; and Cystadrops that is under pre-registration in the European Union for the treatment of ocular cystinosis. Its product development pipeline also includes methadone that is under phase III b clinical trial to treat cancer related pain; Citrafleet, which is under Phase III clinical trials for colonoscopy; Graspa, which is under pre-filing stage in the European Union for acute lymphoblastic leukemia, as well as under phase II b clinical trials for acute myeloid leukemia; and REC 0438 that is under phase I clinical trial in the European Union for treating overactive bladder in patients with spinal lesions. Further, the company produces pharmaceutical chemicals, such as active pharmaceutical ingredients and intermediates. It has operations in Europe, Australasia, Africa, and the United States. The company was founded in 1926 and is headquartered in Milan, Italy.

3,923 Employees
Last Reported Date: 03/6/15
Founded in 1926

recordati spa (RCDTF) Top Compensated Officers

Chairman, Chief Executive Officer and General...
Total Annual Compensation: €1.4M
Compensation as of Fiscal Year 2013.

recordati spa (RCDTF) Key Developments

Recordati Announces Dividend, Payable from April 22, 2015

As proposed by the Board of Directors, the shareholders of Recordati approved a dividend of €0.24 per share, in full balance of the interim 2014 dividend of €0.26, to be paid to all shares outstanding at ex-dividend date, excluding those in treasury stock, as from April 22, 2015 with record date of April 21, 2015 and ex-dividend date of April 20, 2015.

Recordati Spa Announces Consolidated Earnings Results for the Full Year of 2014

Recordati SpA announced consolidated earnings results for the full year of 2014. For the year, the company reported revenues of €987,356,000 compared with €941,630,000 for the same period a year ago. Operating income was €231,030,000 compared with €195,421,000 for the same period a year ago. Pretax income was €214,775,000 compared with €180,796,000 for the same period a year ago. Net income attributable to equity holders of the parent was €161,187,000 or €0.771 per diluted share compared with €133,678,000 or €0.631 per diluted share for the same period a year ago.

Pierre Fabre Extends Collaboration Deals on Expansion of Paediatric Portfolio with Merck KGaA and Recordati in Germany

Pierre Fabre has announced that its German subsidiary has signed two new partnership deals with Merck KGaA and Recordati to strengthen its paediatric portfolio of products. In particular, Merck and Pierre Fabre have expanded their collaboration to include a promotion agreement for two major products of Merck in paediatrics. Furthermore, the collaboration with Recordati was expanded to encompass two additional products. The partners have not reported any financial detail regarding the extension of the collaboration deal with Merck and Recordati.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RCDTF:US $18.22 USD 0.00

RCDTF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.126.90 CHF +2.90
Faes Farma SA €2.36 EUR +0.03
H Lundbeck A/S kr132.10 DKK +2.00
Shire PLC 5,615 GBp -20.00
Procter & Gamble Co/The $81.00 USD +0.05
View Industry Companies

Industry Analysis


Industry Average

Valuation RCDTF Industry Range
Price/Earnings 21.1x
Price/Sales 3.4x
Price/Book 4.2x
Price/Cash Flow 21.1x
TEV/Sales 3.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RECORDATI SPA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at